All News

21 July 2010

Genentech Provides Update from Avastin FDA Advisory Committee MeetingAntibodies

20 July 2010

Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical NeedAntibodies

20 July 2010

Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic CancerAntibodies

19 July 2010

Amgen gets rapid FDA review for denosumabAntibodies

15 July 2010

AMORFIX LIFE SCIENCES ANNOUNCES GLOBAL LICENSING AGREEMENT FOR THE TREATMENT OF ALS WITH BIOGEN IDECAntibodies

14 July 2010

Peregrine Initiates Second Randomized Phase IIb Lung Cancer Trial Using First-In-Class PS-Targeting Monoclonal Antibody BavituximabAntibodies

13 July 2010

Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for BENLYSTA, a Potential New Treatment for Systemic Lupus ErythematosusAntibodies

12 July 2010

Novartis Obtains Licenses to Develop and Commercialise Two Novel Nanobodies(R)Antibodies

9 July 2010

Adimab Announces Fifth Major Pharmaceutical Partnership in First Year After Launch of Novel Antibody Discovery PlatformAntibodies

9 July 2010

Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII) Presented at the 21st International Congress on Thrombosis in Milan, ItalyAntibodies

8 July 2010

Western States Biopharmaceuticals and University of Colorado Announce Exclusive Licensing Agreement for TCISM Targets to Treat Autoimmune DiseasesAntibodies

7 July 2010

Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast CancerAntibodies

7 July 2010

European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid ArthritisAntibodies

7 July 2010

Genmab Announces Interim Results of Ofatumumab Phase II Study in Multiple SclerosisAntibodies

6 July 2010

Cornerstone Therapeutics Reacquires HMGB1 Protein Technology PlatformAntibodies

2 July 2010

Second Phase III Study Showed Avastin-Containing Regimen Helped Women With Ovarian Cancer Live Longer Without Their Disease Getting WorseAntibodies

1 July 2010

GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreementAntibodies

30 June 2010

XOMA Achieves Planned Enrollment Goal for Phase 2b Clinical Trial of XOMA 052 in Type 2 DiabetesAntibodies

28 June 2010

Theraclone Sciences Technology Uncovers Rare Anti-Influenza AntibodiesAntibodies

28 June 2010

FDA Resets its Decision Date For MotavizumabAntibodies

28 June 2010

Eisai and Morphotek, Inc. Announce Initiation of MORAb-022 Study in Europe for the Treatment of Inflammatory DiseaseAntibodies

27 June 2010

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody ProgramAntibodies

26 June 2010

Preclinical Results With XOMA 052 in Type 2 Diabetes Presented at American Diabetes Association 70th Scientific SessionsAntibodies

25 June 2010

Basilea provides update on phase III program for the antifungal isavuconazoleAntibodies

25 June 2010

Human Genome Sciences Announces Presentation of Additional Phase 3 SLE Study Results for BENLYSTA (Belimumab) at International Congress on SLEAntibodies

25 June 2010

ImmunoGen, Inc. Earns Milestone with Start of SAR650984 Clinical TrialAntibodies

25 June 2010

Anti-GITR Combined with Chemotherapy Achieved Tumor Reduction and Survival Benefit in Animal ModelAntibodies

25 June 2010

Epratuzumab Data From Phase IIB EMBLEM(TM) Study Presented at 9th International Congress on Systemic Lupus ErythematosisAntibodies

24 June 2010

Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial ProgramAntibodies

23 June 2010

FDA Approves Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein OcclusionAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Report Package: “Drug the Undruggable” Technologies

TL1A Inhibitor Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Bispecific Antibodies for Immuno-Oncology & Other Diseases

EpCAM-Targeted Antibodies Pipeline Review